Employees: 03 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 1994-01-15 (32 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: AMOU (40330), Landes
EURL PHARMACIE LALANNE HELENE : revenue, balance sheet and financial ratios
EURL PHARMACIE LALANNE HELENE is a French company
founded 32 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in AMOU (40330),
this company of category PME
shows in 2023 a revenue of 2.3 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL PHARMACIE LALANNE HELENE (SIREN 393731989)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
2 306 207 €
N/C
N/C
N/C
2 193 623 €
2 171 418 €
2 148 493 €
Net income
74 294 €
46 298 €
-5 791 €
45 692 €
1 495 €
1 314 €
15 938 €
6 993 €
7 893 €
EBITDA
N/C
N/C
4 859 €
N/C
N/C
N/C
27 546 €
12 915 €
41 144 €
Net margin
N/C
N/C
-0.3%
N/C
N/C
N/C
0.7%
0.3%
0.4%
Revenue and income statement
In 2025, EURL PHARMACIE LALANNE HELENE generates positive net income of 74 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 8 k€ -> 74 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
74 294 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 31%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
31.478%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
58.117%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution EURL PHARMACIE LALANNE HELENE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
80.925
82.902
75.953
66.257
55.833
47.206
46.029
28.293
31.478
Financial autonomy
49.888
48.591
50.882
53.785
53.221
56.375
56.021
56.703
58.117
Repayment capacity
17.465
156.17
29.214
None
None
None
-34.509
None
None
Cash flow / Revenue
1.566%
0.177%
0.871%
None%
None%
None%
-0.412%
None%
None%
Sector positioning
Debt ratio
31.482025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good
In 2025, the debt ratio of EURL PHARMACIE LALANNE HE... (31.48) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
58.12%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of EURL PHARMACIE LALANNE HE... (58.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
-34.51 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Excellent
In 2023, the repayment capacity of EURL PHARMACIE LALANNE HE... (-34.51) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 139.19. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
139.195
Liquidity indicators evolution EURL PHARMACIE LALANNE HELENE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
189.28
201.203
0.0
0.0
0.0
171.876
137.143
110.394
139.195
Interest coverage
19.592
53.202
21.575
None
None
None
35.398
None
None
Sector positioning
Liquidity ratio
139.192025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average
In 2025, the liquidity ratio of EURL PHARMACIE LALANNE HE... (139.19) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
35.4x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Excellent
In 2023, the interest coverage of EURL PHARMACIE LALANNE HE... (35.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution EURL PHARMACIE LALANNE HELENE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
99 647 €
125 855 €
-49 400 €
0 €
0 €
0 €
137 634 €
0 €
0 €
Inventory turnover (days)
22
21
0
0
0
0
21
0
0
Customer payment term (days)
0
0
0
0
0
0
0
0
0
Supplier payment term (days)
20
25
23
0
0
0
27
0
0
Positioning of EURL PHARMACIE LALANNE HELENE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of EURL PHARMACIE LALANNE HELENE is estimated at
1 180 169 €
(range 800 868€ - 1 851 847€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
800k€1180k€1851k€
1 180 169 €Range: 800 868€ - 1 851 847€
NAF 5 année 2025
Valuation method used
Net Income Multiple
74 294 €
×
15.9x
=1 180 169 €
Range: 800 868€ - 1 851 848€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL PHARMACIE LALANNE HELENE with other companies in the same sector:
Frequently asked questions about EURL PHARMACIE LALANNE HELENE
What is the revenue of EURL PHARMACIE LALANNE HELENE ?
The revenue of EURL PHARMACIE LALANNE HELENE in 2023 is 2.3 M€.
Is EURL PHARMACIE LALANNE HELENE profitable?
Yes, EURL PHARMACIE LALANNE HELENE generated a net profit of 74 k€ in 2025.
Where is the headquarters of EURL PHARMACIE LALANNE HELENE ?
The headquarters of EURL PHARMACIE LALANNE HELENE is located in AMOU (40330), in the department Landes.
Where to find the tax return of EURL PHARMACIE LALANNE HELENE ?
The tax return of EURL PHARMACIE LALANNE HELENE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL PHARMACIE LALANNE HELENE operate?
EURL PHARMACIE LALANNE HELENE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart